You are here: News > New Research Supports EB Cancer Trial

New Research Supports EB Cancer Trial

New Research Supports EB Cancer Trial

New research shows that a drug, Rigosertib, may be a safe and effective way of treating the aggressive form of cancer caused by some types of EB, paving the way for a DEBRA funded human clinical trial of the treatment.

Some types of EB cause an aggressive and ultimately fatal form of the skin cancer Squamous Cell Carcinoma (SCC), which is generally not responsive to conventional cancer treatments such as radiotherapy and chemotherapy. 

The findings of a preclinical study, involving both mice and cultured human cells from people with EB who have SCC, indicate that the drug Rigosertib can slow the growth of tumours and kill cancerous cells while leaving healthy cells unharmed. 

Our Policy On Animal Testing 

During the study, Rigosertib was delivered by injection into the bloodstream and shown to affect cancer cells throughout the body. During the upcoming trial which will build on this work, participants will have the option to take the drug as a pill, as a liquid, or into the bloodstream through an IV line.

“EB patients' cancers metastasize (spread) very rapidly, so a systemic drug [one that works throughout the whole body] should target all the cancer cells in the patient," says lead investigator Dr Andrew South.

“We hope that the drug will be a cure for the cancer. If we can reduce the cancer, or even reduce the spread of the cancer, that is going to improve patients' quality of life and extend their lifespan."

This study is an important step forward in proving the safety and efficacy of Rigosertib. A DEBRA funded human clinical trial of the drug will begin recruiting participants this summer.

Find out more about the upcoming trial here.

 

 

Make a difference

Make a difference

Please help us fund vital healthcare such as specialist EB nurses as well as research, care and life-changing support. 

Donate Today